Scientific rationale for developing potent RBD-based vaccines targeting COVID-19.
Scientific rationale for developing potent RBD-based vaccines targeting COVID-19.
复制标题
DOI：
10.1038/s41541-021-00393-6
复制
发表时间：
2021-10-28
期刊：
影响因子：
9.2
通讯作者：
Vaughn DW
中科院分区：
文献类型：
--
作者：
Kleanthous H;Silverman JM;Makar KW;Yoon IK;Jackson N;Vaughn DW
为全球人口接种COVID-19疫苗是一项重大的科学、后勤和道德挑战。尽管几种全长Spike（S）蛋白疫苗的快速开发和授权，但全球需求超过了目前的供应，需要安全、有效、大批量、负担得起的疫苗来填补这一空白，特别是在低收入和中等收入国家。基于SARS-CoV-2 S蛋白受体结合域（RBD）的疫苗是否可以填补这一空白一直存在争议，特别是关于其是否适合保护人们免受新出现的病毒变异的影响。考虑到在自然感染或疫苗接种后靶向RBD的中和抗体（nAb）（保护的关键生物标志物）的引发的优势，选择RBD作为唯一的疫苗免疫原是有价值的。由于其高产生产和制造潜力，基于RBD的疫苗以负担得起的成本提供了大量温度稳定的剂量。此外，由于RBD优先将免疫应答集中于有效的和最近公认的交叉保护决定簇，因此该域可能是未来泛肉瘤病毒疫苗开发的核心。在这项研究中，我们回顾了支持RBD作为疫苗免疫原与全长S蛋白疫苗相比在体液和细胞免疫应答方面对原型大流行SARS-CoV-2分离株和新出现的关注变体的非劣效性的数据。
Vaccination of the global population against COVID-19 is a great scientific, logistical, and moral challenge. Despite the rapid development and authorization of several full-length Spike (S) protein vaccines, the global demand outweighs the current supply and there is a need for safe, potent, high-volume, affordable vaccines that can fill this gap, especially in low- and middle-income countries. Whether SARS-CoV-2 S-protein receptor-binding domain (RBD)-based vaccines could fill this gap has been debated, especially with regards to its suitability to protect against emerging viral variants of concern. Given a predominance for elicitation of neutralizing antibodies (nAbs) that target RBD following natural infection or vaccination, a key biomarker of protection, there is merit for selection of RBD as a sole vaccine immunogen. With its high-yielding production and manufacturing potential, RBD-based vaccines offer an abundance of temperature-stable doses at an affordable cost. In addition, as the RBD preferentially focuses the immune response to potent and recently recognized cross-protective determinants, this domain may be central to the development of future pan-sarbecovirus vaccines. In this study, we review the data supporting the non-inferiority of RBD as a vaccine immunogen compared to full-length S-protein vaccines with respect to humoral and cellular immune responses against both the prototype pandemic SARS-CoV-2 isolate and emerging variants of concern.
登录
查看更多内容
影响因子：
64.8
作者：
Barnes CO;Jette CA;Abernathy ME;Dam KA;Esswein SR;Gristick HB;Malyutin AG;Sharaf NG;Huey-Tubman KE;Lee YE;Robbiani DF;Nussenzweig MC;West AP Jr;Bjorkman PJ
通讯作者：
Bjorkman PJ
影响因子：
64.8
作者：
Gaebler C;Wang Z;Lorenzi JCC;Muecksch F;Finkin S;Tokuyama M;Cho A;Jankovic M;Schaefer-Babajew D;Oliveira TY;Cipolla M;Viant C;Barnes CO;Bram Y;Breton G;Hägglöf T;Mendoza P;Hurley A;Turroja M;Gordon K;Millard KG;Ramos V;Schmidt F;Weisblum Y;Jha D;Tankelevich M;Martinez-Delgado G;Yee J;Patel R;Dizon J;Unson-O'Brien C;Shimeliovich I;Robbiani DF;Zhao Z;Gazumyan A;Schwartz RE;Hatziioannou T;Bjorkman PJ;Mehandru S;Bieniasz PD;Caskey M;Nussenzweig MC
通讯作者：
Nussenzweig MC
DOI：
10.1016/j.str.2021.05.014
发表时间：
2021-07-01
期刊：
Structure (London, England : 1993)
影响因子：
--
作者：
Cerutti G;Rapp M;Guo Y;Bahna F;Bimela J;Reddem ER;Yu J;Wang P;Liu L;Huang Y;Ho DD;Kwong PD;Sheng Z;Shapiro L
通讯作者：
Shapiro L
影响因子：
64.5
作者：
Dejnirattisai W;Zhou D;Ginn HM;Duyvesteyn HME;Supasa P;Case JB;Zhao Y;Walter TS;Mentzer AJ;Liu C;Wang B;Paesen GC;Slon-Campos J;López-Camacho C;Kafai NM;Bailey AL;Chen RE;Ying B;Thompson C;Bolton J;Fyfe A;Gupta S;Tan TK;Gilbert-Jaramillo J;James W;Knight M;Carroll MW;Skelly D;Dold C;Peng Y;Levin R;Dong T;Pollard AJ;Knight JC;Klenerman P;Temperton N;Hall DR;Williams MA;Paterson NG;Bertram FKR;Siebert CA;Clare DK;Howe A;Radecke J;Song Y;Townsend AR;Huang KA;Fry EE;Mongkolsapaya J;Diamond MS;Ren J;Stuart DI;Screaton GR
通讯作者：
Screaton GR
DOI：
10.1073/pnas.2106845118
发表时间：
2021-09-21
影响因子：
11.1
作者：
Dalvie NC;Rodriguez-Aponte SA;Hartwell BL;Tostanoski LH;Biedermann AM;Crowell LE;Kaur K;Kumru OS;Carter L;Yu J;Chang A;McMahan K;Courant T;Lebas C;Lemnios AA;Rodrigues KA;Silva M;Johnston RS;Naranjo CA;Tracey MK;Brady JR;Whittaker CA;Yun D;Brunette N;Wang JY;Walkey C;Fiala B;Kar S;Porto M;Lok M;Andersen H;Lewis MG;Love KR;Camp DL;Silverman JM;Kleanthous H;Joshi SB;Volkin DB;Dubois PM;Collin N;King NP;Barouch DH;Irvine DJ;Love JC
通讯作者：
Love JC